Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma

Trial Profile

An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Atezolizumab (Primary) ; Rogaratinib (Primary)
  • Indications Bladder cancer; Carcinoma; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FORT-2
  • Sponsors Bayer
  • Most Recent Events

    • 09 Jan 2019 Planned number of patients changed from 190 to 210.
    • 23 Oct 2018 Trial design presented at the 43rd European Society for Medical Oncology Congress
    • 30 Aug 2018 Planned End Date changed from 19 Jan 2022 to 25 Jul 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top